AC
AQST icon

Ascend Capital’s Aquestive Therapeutics AQST Stock Holding History

Ascend Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$3.16M Buy
+180,610
New +$2.98M 0.16% 115

Other funds holding AQST

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ascend Capital's AQST Position: Q3 2018 in Review

Ascend Capital opened a new position in Aquestive Therapeutics (AQST) in Q3 2018: 180,610 shares worth $3.16M. The stake represents 0.16% of the portfolio and ranks #115 among its holdings.

44 funds tracked by Wall St. Rank hold AQST as of Q3 2018.

  • Ascend Capital held 180,610 shares of Aquestive Therapeutics worth $3.16M as of Q3 2018.
  • Aquestive Therapeutics was a new Ascend Capital position in Q3 2018.
  • Aquestive Therapeutics made up 0.16% of Ascend Capital's portfolio in Q3 2018, its #115 holding.
  • 44 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.